 | |
| Clinical data | |
|---|---|
| Other names | PPI-668 |
| Routes of administration | By mouth[1] |
| Drug class | NS5A inhibitor[2] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C42H50N8O6 |
| Molar mass | 762.912 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ravidasvir is a medication used to treat hepatitis C.[1] It is typically used together with sofosbuvir with a 97% cure rate.[4] It can be used in people infected with both hepatitis C and HIV/AIDS.[4] It is taken by mouth.[1]
Side effects are generally minor.[3] In people with diabetes, low blood sugar may occur.[3] In those who also have hepatitis B reactivation may occur.[3] It is a NS5A inhibitor.[2]
Ravidasvir was approved for medical use in Malaysia and Egypt in 2021.[4] It is on the World Health Organization's List of Essential Medicines.[5] A 12 week course of treatment is expected to cost about 300 to 500 USD.[2]
References
edit- ^ a b c d "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 10 September 2023. Retrieved 10 September 2023.
- ^ a b c "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi". dndi.org. 14 June 2021. Archived from the original on 7 April 2023. Retrieved 10 September 2023.
- ^ a b c d "24th WHO Expert Committee on Selection and Use of Essential Medicines Expert review" (PDF). WHO. WHO. Archived (PDF) from the original on 10 September 2023. Retrieved 10 September 2023.
- ^ a b c "Ravidasvir + sofosbuvir | DNDi". dndi.org. 31 December 2015. Archived from the original on 21 May 2023. Retrieved 10 September 2023.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.